Peter Sonkin, MD
Retina Specialist · Nashville, TNNPI 1003991167
Payments from drug & device makers
Across 52 payments — averaging $18,259 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$948K
- Harrow Eye, LLC$316
- Genentech USA, Inc.$167
- Novartis$78
- Astellas Pharma US Inc$75
- Bausch & Lomb, A Division Of Bausch Health US, LLC$44
- plus $264 from 8 others
What the payments were for
- Food & beverage$9270%
- Gifts$170%
- Ownership interest$192,16720%
- Other$756,33380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 17 | $948,500 |
| Harrow Eye, LLC | 2 | $316 |
| Genentech USA, Inc. | 9 | $167 |
| Novartis | 5 | $78 |
| Astellas Pharma US Inc | 3 | $75 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $44 |
| Apellis Pharmaceuticals, Inc. | 2 | $44 |
| Alimera Sciences, Inc. | 2 | $43 |
| Mallinckrodt Enterprises LLC | 2 | $43 |
| Carl Zeiss Meditec, Inc. | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| AbbVie(2 entities) | 2 | $31 |
| Amgen | 1 | $16 |
| Regeneron | 1 | $12 |
How this compares
$949,445 in reported general payments places this provider in the 85th percentile of 58 retina specialist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 231 | $12,114 |
| TobradexTobramycin/Dexamethasone | 33 | $8,750 |
| Ketorolac Tromethamine | 232 | $5,055 |
| Alphagan PBrimonidine Tartrate | 12 | $3,320 |
| Brimonidine Tartrate | 45 | $1,801 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 13 | $820 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 39 | $734 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 39 | $442 |
| Atropine Sulfate | 12 | $433 |
| Ciprofloxacin Hcl | 26 | $358 |
| Latanoprost | 14 | $246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieAlphagan P | $31 | $3,32012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 58 retina specialist providers in Tennessee.
Other retina specialist in Nashville
- Carl AwhNashville$9.6M
- Eric SchneiderNashville$4M
- Brandon BusbeeNashville$1.7M
- Akshay ThomasNashville$807K
- Everton ArrindellNashville$279K
- David ReichsteinNashville$176K
- Marcus SolomonNashville$114K
- Brigid MarshallNashville$105K
- Franco RecchiaNashville$72K
- Roy WallaceNashville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.